Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with major unmet medical needs. The company’s lead program is TH103, an investigational anti-VEGF therapy designed for exudative and neovascular retinal conditions, including neovascular age-related macular degeneration. Kalaris Therapeutics also works on extending TH103’s use across other retinal disorders such as diabetic macular edema and retinal vein occlusion. Its current business centers on ophthalmology and biotechnology, where it aims to address sight-threatening diseases through targeted retinal therapies. The company is headquartered in the United States and operates as a specialist developer within the broader healthcare market.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Andrew Oxtoby

Employees

20

Headquarters

Berkeley Heights, NJ, United States

Website

kalaristx.com